Benzamidine

Identification

Name
Benzamidine
Accession Number
DB03127  (EXPT00669)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
KUE3ZY3J1F
CAS number
618-39-3
Weight
Average: 121.1598
Monoisotopic: 121.076573298
Chemical Formula
C7H9N2
InChI Key
PXXJHWLDUBFPOL-UHFFFAOYSA-O
InChI
InChI=1S/C7H8N2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H3,8,9)/p+1
IUPAC Name
[amino(phenyl)methylidene]azanium
SMILES
NC(=[NH2+])C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UKallikrein-6Not AvailableHuman
UTrypsin-2Not AvailableHuman
UTrypsin-3Not AvailableHuman
UCopper transport protein ATOX1Not AvailableHuman
UEnoyl-CoA delta isomerase 1, mitochondrialNot AvailableHuman
UTrypsinNot AvailableStreptomyces griseus
USuppressor of tumorigenicity 14 proteinNot AvailableHuman
UUrokinase-type plasminogen activatorNot AvailableHuman
UTrypsin-1Not AvailableHuman
UCasein kinase II subunit alphaNot AvailableHuman
UKallikrein-1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Benzamidine.Approved, Investigational
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Benzamidine.Approved, Investigational
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Benzamidine.Approved, Illicit, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Benzamidine.Experimental, Investigational
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Benzamidine.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Benzamidine.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Benzamidine.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Benzamidine.Approved, Investigational
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Benzamidine.Approved
BoceprevirThe serum concentration of Benzamidine can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Benzamidine.Approved, Investigational
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Benzamidine.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Benzamidine.Approved
CarbamazepineThe metabolism of Benzamidine can be increased when combined with Carbamazepine.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Benzamidine.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Benzamidine.Approved, Investigational, Vet Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Benzamidine is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Benzamidine.Approved, Investigational, Vet Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Benzamidine.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Benzamidine.Approved, Investigational
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Benzamidine.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Benzamidine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Benzamidine.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Benzamidine.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Benzamidine.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Benzamidine.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Benzamidine.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Benzamidine.Approved, Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Benzamidine.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Benzamidine.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Benzamidine.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Benzamidine.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Benzamidine.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Benzamidine.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Benzamidine.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Benzamidine.Approved, Investigational, Vet Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Benzamidine.Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Benzamidine.Approved
GarlicThe serum concentration of Benzamidine can be decreased when it is combined with Garlic.Approved, Nutraceutical
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Benzamidine.Approved
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Benzamidine.Experimental
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Benzamidine.Experimental
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Benzamidine.Approved, Investigational
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Benzamidine.Experimental, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Benzamidine.Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Benzamidine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Benzamidine.Approved, Illicit
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Benzamidine.Approved, Withdrawn
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Benzamidine.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Benzamidine.Investigational
PethidineThe risk or severity of adverse effects can be increased when Benzamidine is combined with Pethidine.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Benzamidine.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Benzamidine.Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Benzamidine.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Benzamidine.Approved
St. John's WortThe metabolism of Benzamidine can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Benzamidine.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Benzamidine is combined with Temsirolimus.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Benzamidine.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Benzamidine.Approved, Investigational
TipranavirThe serum concentration of Benzamidine can be decreased when it is combined with Tipranavir.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Benzamidine.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Benzamidine.Approved
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Benzamidine.Approved, Investigational
VerapamilThe metabolism of Verapamil can be decreased when combined with Benzamidine.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Benzamidine.Approved
Food Interactions
Not Available

References

Synthesis Reference

Takayuki Hara, Toru Minoshima, Masayasu Tabe, "Benzamidine derivatives and process for production thereof." U.S. Patent US20050101675, issued May 12, 2005.

US20050101675
General References
Not Available
External Links
KEGG Compound
C01784
PubChem Compound
444655
PubChem Substance
46504844
ChemSpider
392524
BindingDB
772
ChEBI
41033
Therapeutic Targets Database
DNC000295
HET
BAM
Wikipedia
Benzamidine
PDB Entries
1c1n / 1c5o / 1c5p / 1c5z / 1f5k / 1hj8 / 1tio / 1xx4 / 1zvw / 2anw
show 22 more

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.57 mg/mLALOGPS
logP-0.8ALOGPS
logP0.89ChemAxon
logS-1.6ALOGPS
pKa (Strongest Basic)11.53ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area51.61 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity48.53 m3·mol-1ChemAxon
Polarizability13.25 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5678
Blood Brain Barrier+0.8661
Caco-2 permeable-0.6125
P-glycoprotein substrateNon-substrate0.7427
P-glycoprotein inhibitor INon-inhibitor0.9915
P-glycoprotein inhibitor IINon-inhibitor0.9871
Renal organic cation transporterNon-inhibitor0.7423
CYP450 2C9 substrateNon-substrate0.7926
CYP450 2D6 substrateNon-substrate0.7624
CYP450 3A4 substrateNon-substrate0.8497
CYP450 1A2 substrateNon-inhibitor0.9705
CYP450 2C9 inhibitorNon-inhibitor0.958
CYP450 2D6 inhibitorNon-inhibitor0.9518
CYP450 2C19 inhibitorNon-inhibitor0.9862
CYP450 3A4 inhibitorNon-inhibitor0.9454
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9616
Ames testNon AMES toxic0.8675
CarcinogenicityNon-carcinogens0.7273
BiodegradationNot ready biodegradable0.6826
Rat acute toxicity2.5986 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9848
hERG inhibition (predictor II)Non-inhibitor0.9628
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Carboximidamides / Carboxamidines / Organopnictogen compounds / Hydrocarbon derivatives / Organic cations
Substituents
Monocyclic benzene moiety / Carboximidamide / Carboxylic acid amidine / Amidine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Organic cation / Aromatic homomonocyclic compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic prote...
Gene Name
KLK6
Uniprot ID
Q92876
Uniprot Name
Kallikrein-6
Molecular Weight
26855.525 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
In the ileum, may be involved in defensin processing, including DEFA5.
Gene Name
PRSS2
Uniprot ID
P07478
Uniprot Name
Trypsin-2
Molecular Weight
26487.55 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type peptidase activity
Specific Function
Digestive protease specialized for the degradation of trypsin inhibitors. In the ileum, may be involved in defensin processing, including DEFA5.
Gene Name
PRSS3
Uniprot ID
P35030
Uniprot Name
Trypsin-3
Molecular Weight
32528.565 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Metallochaperone activity
Specific Function
Binds and deliver cytosolic copper to the copper ATPase proteins. May be important in cellular antioxidant defense.
Gene Name
ATOX1
Uniprot ID
O00244
Uniprot Name
Copper transport protein ATOX1
Molecular Weight
7401.575 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Intramolecular oxidoreductase activity
Specific Function
Able to isomerize both 3-cis and 3-trans double bonds into the 2-trans form in a range of enoyl-CoA species.
Gene Name
ECI1
Uniprot ID
P42126
Uniprot Name
Enoyl-CoA delta isomerase 1, mitochondrial
Molecular Weight
32815.635 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Streptomyces griseus
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Not Available
Gene Name
sprT
Uniprot ID
P00775
Uniprot Name
Trypsin
Molecular Weight
26776.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type peptidase activity
Specific Function
Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the...
Gene Name
ST14
Uniprot ID
Q9Y5Y6
Uniprot Name
Suppressor of tumorigenicity 14 protein
Molecular Weight
94769.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
Gene Name
PLAU
Uniprot ID
P00749
Uniprot Name
Urokinase-type plasminogen activator
Molecular Weight
48507.09 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Has activity against the synthetic substrates Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-Mec. The single-chain form is more active than the two-chain form aga...
Gene Name
PRSS1
Uniprot ID
P07477
Uniprot Name
Trypsin-1
Molecular Weight
26557.88 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein serine/threonine kinase activity
Specific Function
Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated ser...
Gene Name
CSNK2A1
Uniprot ID
P68400
Uniprot Name
Casein kinase II subunit alpha
Molecular Weight
45143.25 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.
Gene Name
KLK1
Uniprot ID
P06870
Uniprot Name
Kallikrein-1
Molecular Weight
28889.425 Da
References
  1. Sousa MO, Miranda TL, Costa EB, Bittar ER, Santoro MM, Figueiredo AF: Linear competitive inhibition of human tissue kallikrein by 4-aminobenzamidine and benzamidine and linear mixed inhibition by 4-nitroaniline and aniline. Braz J Med Biol Res. 2001 Jan;34(1):35-44. [PubMed:11151026]

Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 07:12